Los Angeles Capital Management LLC Sells 44,800 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Los Angeles Capital Management LLC reduced its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 16.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 232,081 shares of the biopharmaceutical company’s stock after selling 44,800 shares during the period. Los Angeles Capital Management LLC’s holdings in Vanda Pharmaceuticals were worth $1,112,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in VNDA. Intech Investment Management LLC purchased a new stake in shares of Vanda Pharmaceuticals in the third quarter worth approximately $84,000. SG Americas Securities LLC raised its holdings in shares of Vanda Pharmaceuticals by 26.8% in the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 5,459 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Vanda Pharmaceuticals in the third quarter worth approximately $143,000. Verition Fund Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 7.8% in the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 2,927 shares during the period. Finally, Franklin Resources Inc. raised its holdings in shares of Vanda Pharmaceuticals by 8.8% in the third quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 4,449 shares during the period. Institutional investors own 88.14% of the company’s stock.

Insider Transactions at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the stock in a transaction dated Friday, February 28th. The shares were acquired at an average cost of $4.76 per share, for a total transaction of $47,600.00. Following the acquisition, the chief executive officer now owns 2,361,730 shares of the company’s stock, valued at approximately $11,241,834.80. This represents a 0.43 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders acquired 22,000 shares of company stock valued at $100,980. Company insiders own 8.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on VNDA shares. StockNews.com started coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a “hold” rating on the stock. HC Wainwright lifted their price target on shares of Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th.

Vanda Pharmaceuticals Stock Performance

Vanda Pharmaceuticals stock opened at $4.76 on Friday. The company has a 50 day moving average price of $4.59 and a 200-day moving average price of $4.79. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.71 and a fifty-two week high of $6.75. The company has a market capitalization of $277.58 million, a PE ratio of -14.88 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The firm had revenue of $53.19 million during the quarter, compared to analysts’ expectations of $51.00 million. On average, analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.